Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes

Immunotherapy is set to transform the treatment paradigm for thyroid cancers, although remaining hurdles, the disquietingly low baseline immunogenicity of differentiated tumors, the rapid, capricious emergence of resistance, and complex immune-related endocrine toxicities, must be systematically addressed. Success in this arena will hinge on utilitarian biomarker-based cohort selection, the discovery of fresh immunogenic epitopes, and the meticulous design of synergistic treatment combinations. The synergistic leverage of genomic, transcriptomic, and immune landscape dissection, coupled with cutting-edge engineered lymphocyte platforms and engineered oncolytic vectors, may finally position immunotherapy as an unassailable pillar of bespoke medicine for advanced thyroid carcinomas.